Skip to main content

Commercialization of catalytic enhancers targeting IDO1 for multiple sclerosis

Searching for OpenAIRE data...


Polyamines and Kynurenines at the Intersection of Immune Modulation.

Author(s): Elisa Proietti; Sofia Rossini; Ursula Grohmann; Giada Mondanelli
Published in: Trends in Immunology, 1, 2020, Page(s) 1037 - 1050, ISSN 1471-4906
Publisher: Elsevier BV
DOI: 10.1016/

Amino Acid Metabolism in Rheumatoid Arthritis: Friend or Foe?

Author(s): Eleonora Panfili; Roberto Gerli; Ursula Grohmann; Maria Teresa Pallotta
Published in: Biomolecules, 1, 2020, Page(s) 1 - 22, ISSN 2218-273X
Publisher: MDPI
DOI: 10.3390/biom10091280

Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme

Author(s): Maria Teresa Pallotta; Sofia Rossini; Chiara Suvieri; Alice Coletti; Ciriana Orabona; Antonio Macchiarulo; Claudia Volpi; Ursula Grohmann
Published in: The FEBS Journal, 1, 2021, ISSN 1742-464X
Publisher: Blackwell Publishing Inc.
DOI: 10.1111/febs.16086

Critical Assessment of a Structure-Based Screening Campaign for IDO1 Inhibitors: Tips and Pitfalls

Author(s): Andrea Mammoli; Elisa Bianconi; Luana Ruta; Alessandra Riccio; Carlo Bigiotti; Maria Souma; Andrea Carotti; Sofia Rossini; Chiara Suvieri; Maria Teresa Pallotta; Ursula Grohmann; Emidio Camaioni; Antonio Macchiarulo
Published in: International Journal of Molecular Sciences, 2, 2022, Page(s) 3981, ISSN 1661-6596
Publisher: MDPI Center
DOI: 10.3390/ijms23073981

Reply to Han et al.: On track for an IDO1-based personalized therapy in autoimmunity

Author(s): Giada Mondanelli, Agostinho Carvalho, Paolo Puccetti, Ursula Grohmann, Claudia Volpi
Published in: Proceedings of the National Academy of Sciences of the United States of America, 2020, Page(s) 24037 - 24038, ISSN 0027-8424
Publisher: National Academy of Sciences
DOI: 10.1073/pnas.2016277117